Cargando…
Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy
The voltage-gated Kv10.2 potassium channel, encoded by KCNH5, is broadly expressed in mammalian tissues, including the brain. Its potential mechanism remains unclear. According to previous studies, dysfunction of Kv10.2 may be associated with epileptic encephalopathies and autism spectrum disorder (...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301331/ https://www.ncbi.nlm.nih.gov/pubmed/35874597 http://dx.doi.org/10.3389/fped.2022.858008 |
_version_ | 1784751408358096896 |
---|---|
author | Hu, Xiufu Yang, Junli Zhang, Man Fang, Tie Gao, Qin Liu, Xinjie |
author_facet | Hu, Xiufu Yang, Junli Zhang, Man Fang, Tie Gao, Qin Liu, Xinjie |
author_sort | Hu, Xiufu |
collection | PubMed |
description | The voltage-gated Kv10.2 potassium channel, encoded by KCNH5, is broadly expressed in mammalian tissues, including the brain. Its potential mechanism remains unclear. According to previous studies, dysfunction of Kv10.2 may be associated with epileptic encephalopathies and autism spectrum disorder (ASD). To date, only one disease-causing mutation of KCNH5 has been reported, and it involves a case that presented with seizures and autism symptoms. In this study, we discovered and characterized three de novo mutations in KCNH5 that potentially caused severe conditions observed in three Chinese children. All of them experienced seizures, two of them presented with epileptic encephalopathy, one of them presented with ASD, and one did not relapse after drug withdrawal. Notably, treatment with antiepileptic drugs (AEDs) was effective in all patients whose epileptic seizures were controlled. The structures of the proteins resulting from the mutations were predicted in two of the three cases. This provides powerful insight into clinical heterogeneity and genotype-phenotype correlation in KCNH5-related diseases. |
format | Online Article Text |
id | pubmed-9301331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93013312022-07-22 Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy Hu, Xiufu Yang, Junli Zhang, Man Fang, Tie Gao, Qin Liu, Xinjie Front Pediatr Pediatrics The voltage-gated Kv10.2 potassium channel, encoded by KCNH5, is broadly expressed in mammalian tissues, including the brain. Its potential mechanism remains unclear. According to previous studies, dysfunction of Kv10.2 may be associated with epileptic encephalopathies and autism spectrum disorder (ASD). To date, only one disease-causing mutation of KCNH5 has been reported, and it involves a case that presented with seizures and autism symptoms. In this study, we discovered and characterized three de novo mutations in KCNH5 that potentially caused severe conditions observed in three Chinese children. All of them experienced seizures, two of them presented with epileptic encephalopathy, one of them presented with ASD, and one did not relapse after drug withdrawal. Notably, treatment with antiepileptic drugs (AEDs) was effective in all patients whose epileptic seizures were controlled. The structures of the proteins resulting from the mutations were predicted in two of the three cases. This provides powerful insight into clinical heterogeneity and genotype-phenotype correlation in KCNH5-related diseases. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9301331/ /pubmed/35874597 http://dx.doi.org/10.3389/fped.2022.858008 Text en Copyright © 2022 Hu, Yang, Zhang, Fang, Gao and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Hu, Xiufu Yang, Junli Zhang, Man Fang, Tie Gao, Qin Liu, Xinjie Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title | Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title_full | Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title_fullStr | Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title_full_unstemmed | Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title_short | Clinical Feature, Treatment, and KCNH5 Mutations in Epilepsy |
title_sort | clinical feature, treatment, and kcnh5 mutations in epilepsy |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301331/ https://www.ncbi.nlm.nih.gov/pubmed/35874597 http://dx.doi.org/10.3389/fped.2022.858008 |
work_keys_str_mv | AT huxiufu clinicalfeaturetreatmentandkcnh5mutationsinepilepsy AT yangjunli clinicalfeaturetreatmentandkcnh5mutationsinepilepsy AT zhangman clinicalfeaturetreatmentandkcnh5mutationsinepilepsy AT fangtie clinicalfeaturetreatmentandkcnh5mutationsinepilepsy AT gaoqin clinicalfeaturetreatmentandkcnh5mutationsinepilepsy AT liuxinjie clinicalfeaturetreatmentandkcnh5mutationsinepilepsy |